admin

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its non-invasive organ transplant surveillance solutions are being used to help monitor post-operative graft health in the world’s first successful heart xenotransplantation. A genetically modified pig heart was successfully transplanted into a patient at the University of Maryland Medical Center on January 7, 2022.

Johns Hopkins University led all U.S. institutions in total National Institutes of Health (NIH) funding for federal fiscal year 2021, with more than $820 million in awards, $824,856,274 to be exact. The rest of the top ten institutions were:

After struggling through COVID-19 vaccine production woes in 2021, Emergent BioSolutions has another surprise for its investors in early 2022. 

Last month, Emergent projected revenues of $1.4 billion to $1.5 billion for this year. Now, the company has dropped the figure to $1.3 to $1.4 billion. 

Why the adjustment?

In its quarterly report, Emergent credited its decision to undergo maintenance on its troubled Baltimore Bayview facility “earlier than anticipated,” and to expand the project to set the facility up for “future non-pandemic work.”

USP Developing mRNA Quality Guidelines to help companies and regulators bring innovative medicines to market faster   Rockville, Md., February 23, 2022 – U.S. Pharmacopeia (USP), a global independent scientific organization, is seeking scientific input on new draft guidelines, “Analytical Procedures for mRNA Vaccine Quality.” USP and a group of leading mRNA experts have identified the need for analytical procedures and best practices to support quality assessments for mRNA vaccines and therapies in development pipelines for infectious diseases, cancer, cystic fibrosis and other disorders.

To build public trust and confidence in innovative products like mRNA-based therapies, they must be of good quality, safe, and effective. Since the successful application of mRNA technology is relatively new, regulatory guidelines and industry standards are still evolving. A common approach for assessing mRNA quality would support developers, manufacturers, regulatory agencies, and national control laboratories worldwide, and provide tools to help accelerate the development of safe and effective mRNA-based products.

The AIM-HI Women’s Venture Competition, in its third year, is open for women entrepreneurs! The program provides early-stage funding, coaching, and networking opportunities to women-led oncology startups to address unmet medical needs.

The winning company will receive a total of $1 million in equity investment from AIM-HI and co-investors, subject to due diligence and negotiation. Click here to download the flyer and help spread the word!

Marty Rosendale, Chief Executive Officer of the Maryland Tech Council, joins BioTalk to discuss MTCs Programs, Accessing Capital, and Goals for 2022

Listen now on Google https://bit.ly/3LQZNLR, Apple https://apple.co/3H6Aly4, Spotify https://spoti.fi/3LQkZRW, and Amazon https://amzn.to/3sZxuSR, and TuneIn https://bit.ly/3sU6Af0.